Dec. 8 (UPI) --The U.S. Food and Drug Administration on Monday announced the approval of the first hematopoietic stem cell transplant therapy to treat patients with rare but severe aplastic anemia.
DUBLIN, IRELAND AND LONDON, UK = / ACCESS Newswire / December 8, 2025 / Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., a leader in cell therapy innovation today ...
Study findings showed 86% of patients had early and sustained neutrophil recovery at 100 days. The Food and Drug Administration (FDA) has approved Omisirge ® (omidubicel-onlv) for adults and pediatric ...
What Is Omisirge, and Why Does It Matter? Omisirge (omidubicel-onlv) is a type of cell therapy made from umbilical cord blood. It helps your body make new blood cells after a stem cell transplant.
No cases of BMT-CTN severe acute graft-versus-host disease (GVHD), or chronic GVHD observed Omisirge approved by the FDA on December 5, 2025 for SAA DUBLIN, IRELAND AND LONDON, UK = / ACCESS Newswire ...
The FDA approved omidubicel on December 8, 2025, the same day parent company Ayrmid announced positive results at the 2025 American Society of Hematology Annual Meeting and Exposition. FDA approved ...
DUBLIN, IE AND LONDON, UK / ACCESS Newswire / December 5, 2025 / Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., a leader in cell therapy innovation announces that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results